Cytosorbents (NASDAQ:CTSO) Stock Rating Upgraded by WBB Securities

Cytosorbents (NASDAQ:CTSO) was upgraded by WBB Securities to a “moderate buy” rating in a report issued on Wednesday, Zacks reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a research note on Friday, October 2nd. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $74.83.

Cytosorbents Price Performance

CTSO stock opened at $5.35 on Wednesday. The firm’s 50-day moving average price is $5.61 and its two-hundred day moving average price is $8.11. Cytosorbents has a 12-month low of $2.84 and a 12-month high of $17.28. The stock has a market capitalization of $16.86 million, a price-to-earnings ratio of -0.92 and a beta of 1.37. The company has a current ratio of 0.66, a quick ratio of 0.50 and a debt-to-equity ratio of 4.70.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.73. The firm had revenue of $9.63 million during the quarter, compared to the consensus estimate of $9.38 million. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%. As a group, equities analysts predict that Cytosorbents will post -4.40 earnings per share for the current year.

Insider Activity

In other Cytosorbents news, CEO Phillip Chan bought 200,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was bought at an average price of $0.35 per share, for a total transaction of $70,000.00. Following the completion of the acquisition, the chief executive officer directly owned 1,944,432 shares in the company, valued at $680,551.20. The trade was a 11.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 7.80% of the company’s stock.

Cytosorbents Company Profile

CytoSorbents Corporation is a medical device company that develops blood purification technologies designed to remove harmful substances from the bloodstream. Its products use proprietary, porous polymer adsorbent technology to reduce circulating cytokines, inflammatory mediators, toxins and other substances associated with serious illness.

The company’s principal product, CytoSorb, is an extracorporeal blood purification device used in critical care and other clinical settings. It is designed to help manage excessive inflammation and is used with existing blood-pumping systems.